Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IQWIG

- PMLiVE

IQWiG passes Boehringer lung cancer drug

Germany’s cost assessor says it can extend life in some patients, but benefit it ‘minor'

- PMLiVE

US cancer drug prices ‘not rational’

New research from the medical journal JAMA adds to growing pressure over pricing

- PMLiVE

Access – the only thing that matters

Our job, at its very core, is to get our medicines into the hands of patients

german flag

German pharma market to edge up to $65bn by 2020

Report finds that laws designed to curb drug prices will also slow down growth

- PMLiVE

Final NICE ‘no’ for Celgene’s Imnovid

England’s pricing watchdog says multiple myeloma drug is just too expensive for the NHS

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

Anticipating the future in healthcare

New technologies will be key drivers for change

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Cancer Drugs Fund cull ‘won’t save NHS money’

New survey also finds that oncologists believe the cuts will ‘worsen patient outcomes’

- PMLiVE

German drug cost containment system ‘aids data transparency’

New study by IQWiG suggests similar rules should be rolled out across Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links